VERAPAMIL HYDROCHLORIDE INJECTION USP SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

VERAPAMIL HYDROCHLORIDE

から入手可能:

PFIZER CANADA ULC

ATCコード:

C08DA01

INN（国際名）:

VERAPAMIL

投薬量:

2.5MG

医薬品形態:

SOLUTION

構図:

VERAPAMIL HYDROCHLORIDE 2.5MG

投与経路:

INTRAVENOUS

パッケージ内のユニット:

2ML

処方タイプ:

Prescription

治療領域:

MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS

製品概要:

Active ingredient group (AIG) number: 0113846005; AHFS:

認証ステータス:

APPROVED

承認日:

2004-04-08

製品の特徴

PRODUCT MONOGRAPH
PR
VERAPAMIL HYDROCHLORIDE INJECTION USP
2.5 MG/ML
2 mL Ampoules and Vials
Sterile Solution
_Antiarrhythmic_
Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Date of revision:
May 18, 2021
Control Number: 247539
_Product Monograph – _
_Pr_
_Verapamil Hydrochloride Injection USP _
_Page 2 of 46 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
............................................................................................................
10
DRUG INTERACTIONS
............................................................................................................
14
DOSAGE AND ADMINISTRATION
........................................................................................
26
OVERDOSAGE
..........................................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
30
STORAGE AND STABILITY
....................................................................................................
33
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................ 33
PART II: SCIENTIFIC INFORMATION
..........................................................................................
34
PHARMACEUTICAL INFORMATION
....................................................................................